Krishna Institute of Medical Sciences Limited (BOM:543308)
India
· Delayed Price · Currency is INR | Market Cap | 269.87B |
| Revenue (ttm) | 36.27B |
| Net Income (ttm) | 3.01B |
| Shares Out | n/a |
| EPS (ttm) | 7.51 |
| PE Ratio | 89.75 |
| Forward PE | 60.03 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,089 |
| Average Volume | 56,817 |
| Open | 645.05 |
| Previous Close | 652.10 |
| Day's Range | 645.05 - 679.90 |
| 52-Week Range | 575.55 - 798.00 |
| Beta | n/a |
| RSI | 54.43 |
| Earnings Date | May 12, 2026 |
About BOM:543308
Krishna Institute of Medical Sciences Limited provides medical and health care services under the KIMS Hospitals brand in India. The company offers neurology, neurosurgery, psychiatry, and neuro rehabilitation; cardiology, cardiac and vascular surgery, heart transplant, and cardio rehabilitation; and pulmonology, interventional pulmonology, thoracic surgery, and lung transplant. It also provides medical and surgical gastroenterology, hepatobiliary pancreatic surgery, liver transplant, and bariatric surgery; ear, nose, throat, and head and neck ... [Read more]
Financial Performance
In fiscal year 2025, BOM:543308's revenue was 30.35 billion, an increase of 21.49% compared to the previous year's 24.98 billion. Earnings were 3.85 billion, an increase of 24.03%.
Financial StatementsNews
Krishna Institute of Medical Sciences Transcript: Q3 25/26
Q3 FY26 saw record revenue above INR 1,000 crore, with strong growth in new hospitals but margin pressure from ramp-up costs. Debt has peaked and is expected to moderate as CapEx winds down, while break-even is targeted soon for new units.
Krishna Institute of Medical Sciences Transcript: Q2 25/26
Q2 FY26 saw 23% revenue growth but EBITDA and EPS declined due to new hospital ramp-up costs. Margin expansion is expected as new units break even, with Andhra and Telangana clusters maintaining strong profitability. CGHS price hikes and insurance empanelment will support future margins.
Krishna Institute of Medical Sciences Transcript: Q1 25/26
Revenue grew 26.8% YoY to INR 879 crore, with EBITDA at INR 200 crore and margin at 22.7%. New units in Thane, Bangalore, and Kerala are ramping up, with initial losses expected to neutralize within 12 months. Net debt stands at INR 2,020 crore, and ARPOB is projected to rise as new facilities mature.
Krishna Institute of Medical Sciences Transcript: Q4 24/25
FY25 delivered robust revenue and EBITDA growth, driven by mature clusters and new hospital launches. Margin expansion was supported by higher ARPOB, specialty mix, and technology adoption, with new units expected to turn EBITDA positive within a year.
Krishna Institute of Medical Sciences Transcript: Q3 24/25
Revenue grew 29.7% year-over-year to INR 790 crore, with EBITDA up 36.4% and margin at 25.9%. Expansion continues in Kerala, Maharashtra, and Bangalore, with new hospitals and clinical milestones achieved. Debt and CapEx remain within guided levels, and margins are expected to improve as new specialties ramp up.
Krishna Institute of Medical Sciences Transcript: Q2 24/25
Revenue and EBITDA grew strongly year-over-year and quarter-on-quarter, with margins improving and asset-light expansion underway in Kerala and Maharashtra. Strategic focus remains on Tier 2/3 cities, maintaining low CapEx and stable leverage, while new hospitals may cause a short-term EBITDA drag.
Krishna Institute of Medical Sciences Transcript: Q1 24/25
Revenue and EBITDA grew strongly year-over-year, with ARPOB and margins improving. Expansion continues with new acquisitions and hospital launches, while debt and CapEx are managed within set limits. Margin sustainability is expected despite new hospital drag.